Review



bxpc3 cell line  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    ATCC bxpc3 cell line
    Fig. 1 In-vitro characterization of AT101. A Schematic representation of GPC1 protein and visualization of the aminoacids employed for the mouse immunization. B SDS-PAGE analysis performed in non-reducing and reducing condition to determine the IgM nature of AT101. C Elisa to assess the GPC1 binding activity of AT101, the positive control (CTRL +) was represented by serum of mice immunized with GPC1, the negative control (CTRL-) was performed by only using the goat anti-mouse IgG/IgM antibody conjugated with alkaline phosphatase (AP) without AT101 (n = 3). D Flow cytometry analysis to evaluate GPC1 expression in <t>BXPC3</t> and Jurkat cells using AT101 and the commercial anti-GPC1 antibody as positive control (n = 3). ***, 0.001 < p ≤ 0.0001
    Bxpc3 Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 294 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdac+tissue+array/BxPC-3%3B+Pancreatic+Carcinoma%3B+Human/pm38017492-63-0-12
    Average 96 stars, based on 294 article reviews
    bxpc3 cell line - by Bioz Stars, 2026-09
    96/100 stars

    Images

    1) Product Images from "A novel complement-fixing IgM antibody targeting GPC1 as a useful immunotherapeutic strategy for the treatment of pancreatic ductal adenocarcinoma."

    Article Title: A novel complement-fixing IgM antibody targeting GPC1 as a useful immunotherapeutic strategy for the treatment of pancreatic ductal adenocarcinoma.

    Journal: Journal of translational medicine

    doi: 10.1186/s12967-023-04745-9

    Fig. 1 In-vitro characterization of AT101. A Schematic representation of GPC1 protein and visualization of the aminoacids employed for the mouse immunization. B SDS-PAGE analysis performed in non-reducing and reducing condition to determine the IgM nature of AT101. C Elisa to assess the GPC1 binding activity of AT101, the positive control (CTRL +) was represented by serum of mice immunized with GPC1, the negative control (CTRL-) was performed by only using the goat anti-mouse IgG/IgM antibody conjugated with alkaline phosphatase (AP) without AT101 (n = 3). D Flow cytometry analysis to evaluate GPC1 expression in BXPC3 and Jurkat cells using AT101 and the commercial anti-GPC1 antibody as positive control (n = 3). ***, 0.001 < p ≤ 0.0001
    Figure Legend Snippet: Fig. 1 In-vitro characterization of AT101. A Schematic representation of GPC1 protein and visualization of the aminoacids employed for the mouse immunization. B SDS-PAGE analysis performed in non-reducing and reducing condition to determine the IgM nature of AT101. C Elisa to assess the GPC1 binding activity of AT101, the positive control (CTRL +) was represented by serum of mice immunized with GPC1, the negative control (CTRL-) was performed by only using the goat anti-mouse IgG/IgM antibody conjugated with alkaline phosphatase (AP) without AT101 (n = 3). D Flow cytometry analysis to evaluate GPC1 expression in BXPC3 and Jurkat cells using AT101 and the commercial anti-GPC1 antibody as positive control (n = 3). ***, 0.001 < p ≤ 0.0001

    Techniques Used: In Vitro, SDS Page, Enzyme-linked Immunosorbent Assay, Binding Assay, Activity Assay, Positive Control, Negative Control, Flow Cytometry, Expressing

    Related Articles

    Multiple Displacement Amplification:

    Article Title: Targeting uPAR with an antibody-drug conjugate suppresses tumor growth and reshapes the immune landscape in pancreatic cancer models.
    Article Snippet: .. The cell lines investigated were obtained from the following sources: AsPC- 1 [ATCC American Type Culture Collection (ATCC) #CRL1682], BxPC- 3 (ATCC #CRL- 1687), MIA PaCa- 2 (ATCC #CRMCRL- 1420), MDA- MB- 231 (TNBC, ATCC #CRM- HTB- 26), U937 (ATCC #CRL1593.2), NIH3T3 (ATCC #1658), and 1BR3.6 (ECACC, #90020507). ..

    Cell Culture:

    Article Title: SG33, a vaccine strain of myxoma virus with oncolytic potential, exploits macropinocytosis and clathrin-mediated endocytosis for entry into pancreatic cancer cells
    Article Snippet: .. AsPC-1 (ATCC-CRL-1682) and BxPC-2 (ATCC-CRL-1687) cells were cultured in RPMI (GlutaMAX; Life Technologies) supplemented with 1% penicillin/streptomycin (P/S; Life Technologies). .. MIA-PaCa-2 (ATCC-CRL-1420), RK13 , PDAC012T, PDAC015T, PDAC084T, PDAC087T, and PDAC091T cells were cultured in DMEM (4.5 g/L glucose; Life Technologies) with 1% P/S, as previously described( ).

    Article Title: The nucleolin antagonist N6L and paclitaxel combination treatment could be a new promising therapeutic strategy for pancreatic ductal adenocarcinoma therapy.
    Article Snippet: The N6L was synthesized as stated in a previous study and obtained from Immupharma PLC (London, great Britain) (Destouches et al., 2011b). .. Human PDAC MIA PaCa-2 (ATCC-CRL-1420), PANC-1 (ATCC-CRL1469) and BxPC-3 (ATCC-CRL1687) cell lines were purchased from ATCC (Manassas, USA) and cultured according to manufacturer’s instructions. ..

    other:

    Article Title: Discovery of KRAS(G12D) selective degrader ASP3082
    Article Snippet: Cell Line Table Name Tumor Type KRAS Status Oncogenic Alterations (excluding KRAS) RRID Vendor Catalogue Number Medium AsPC-1 Pancreas G12D SMAD4 (R100T) CVCL_0152 ATCC CRL-1682 RPMI-1640 HPAC Pancreas G12D TP53 (G187R) CVCL_3517 ATCC CRL-2119 RPMI-1640 KP-4 Pancreas G12D - CVCL_1338 JCRB JCRB0182 IMDM PK-1 Pancreas G12D TP53 (M237I) CVCL_4717 RIKEN BRC RCB1972 RPMI-1640 PK-59 Pancreas G12D RAC1 (P29S) CVCL_4897 RIKEN BRC RCB1901 RPMI-1640 PSN1 Pancreas G12R TP53 (K132Q) CVCL_1644 ECACC 94060601 RPMI-1640 (with L-glutamine) PA-TU-8902 Pancreas G12V TP53 (C176S), SPOP (M117I) CVCL_1845 DSMZ ACC 179 DMEM BxPC-3 Pancreas WT TP53 (Y220C) CVCL_0186 ATCC CRL-1687 RPMI-1640 GP2d Colon G12D RHOA (Y34C), PIK3CA( H1047L) CVCL_2450 ECACC 95090714 DMEM (with sodium pyruvate) GP5d Colon G12D RHOA (Y34C), PIK3CA( H1047L) CVCL_1235 ECACC 95090715 DMEM (with sodium pyruvate) SK-CO-1 Colon G12V - CVCL_0626 ATCC HTB-39 EMEM SW-403 Colon G12V PIK3CA (Q546K) CVCL_0545 DSMZ ACC 294 Leibovitz's L-15 HCT 116 Colon G13D CTNNB1 (S45del), PIK3CA (H1047R) CVCL_0291 ATCC CCL-247 McCoy's 5A HT-29 Colon WT TP53 (R273H), PIK3CA (P449T), BRAF (V600E) CVCL_0320 ATCC HTB-38 McCoy's 5A COLO-320 Colon WT TP53 (R248W) CVCL_1989 RIKEN BRC RCB1193 RPMI-1640 NCI-H358 Lung G12C - CVCL_1559 ATCC CRL-5807 RPMI-1640 LCLC-97TM1 Lung G12V - CVCL_1376 DSMZ ACC 388 RPMI-1640 NCI-H1299 Lung WT NRAS (Q61K) CVCL_0060 ATCC CRL-5803 RPMI-1640 A375 Skin WT BRAF (V600E) CVCL_0132 ATCC CRL-1619 DMEM (with sodium pyruvate) T24 Bladder WT HRAS (G12V) CVCL_0554 JCRB JCRB0711 McCoy's 5A



    Similar Products

    86
    Biomax Inc human pdac tissue array
    (A) Representative IHC staining <t>of</t> <t>ITGB3</t> in <t>PDAC</t> tissue microarrays (TMA) showing varying expression levels in non-cancer and cancer tissue sections. (B). High magnification IHC images demonstrating the expression of ITGB3 on normal pancreas and cancer cells with stromal regions. (D-I) . Scatter plots depicting the correlation between ITGB3 and key tumor-associated markers such as HIF-1α (D) , GLUT-1 (E) , VEGFA (F) , Vimentin (G) , COL1A1 (H) , and PECAM1 (I) . Pearson correlation coefficients (R) and p -values indicate statistically significant positive correlation between ITGB3 and these markers. Statistical significance was assessed using a two-tailed unpaired Student’s t-test. All quantitative data represent the mean ± SEM. ∗∗∗∗p < 0.0001.
    Human Pdac Tissue Array, supplied by Biomax Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdac+tissue+array/array+slides+tissue/bio_rxiv__64898__2026__01__15__699725-59-16-21
    Average 86 stars, based on 1 article reviews
    human pdac tissue array - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    90
    TissueArray.com LLC human pdac tissue array
    (A) Representative IHC staining <t>of</t> <t>ITGB3</t> in <t>PDAC</t> tissue microarrays (TMA) showing varying expression levels in non-cancer and cancer tissue sections. (B). High magnification IHC images demonstrating the expression of ITGB3 on normal pancreas and cancer cells with stromal regions. (D-I) . Scatter plots depicting the correlation between ITGB3 and key tumor-associated markers such as HIF-1α (D) , GLUT-1 (E) , VEGFA (F) , Vimentin (G) , COL1A1 (H) , and PECAM1 (I) . Pearson correlation coefficients (R) and p -values indicate statistically significant positive correlation between ITGB3 and these markers. Statistical significance was assessed using a two-tailed unpaired Student’s t-test. All quantitative data represent the mean ± SEM. ∗∗∗∗p < 0.0001.
    Human Pdac Tissue Array, supplied by TissueArray.com LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdac+tissue+array/human+pancreatic+cancer+tissue+array/pm39048609-54-1-9
    Average 90 stars, based on 1 article reviews
    human pdac tissue array - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    TissueArray.com LLC the human pdac tissue array
    STING expression in <t>human</t> <t>PDAC</t> stroma and CAFs. ( a ) Groups categorized by positive, weakly positive, and negative STING expression in PDAC stroma. Representative IHC analysis of STING using a human PDAC tissue array (scale bar, 100 μm). ( b ) Percentages of the indicated groups in 40 PDAC samples. ( c ) Co-immunofluorescence staining for α-SMA (red) and STING (green) in STING positive or weakly positive or negative in stroma. ( d ) 5-AZA (0.1 nM) was administered to CAF1 and CAF2 derived from murine PDACs and incubated for 24 h.
    The Human Pdac Tissue Array, supplied by TissueArray.com LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdac+tissue+array/human+pancreatic+cancer+tissue+array/pmc11269671-39-1-9
    Average 90 stars, based on 1 article reviews
    the human pdac tissue array - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    U.S Biomax Inc human pdac tissue array
    <t>a,</t> <t>Immunohistochemistry</t> staining of LPAR4 in a <t>PDAC</t> tissue array consisted of 15 PDAC samples and 4 samples of normal pancreas. Scale bar is 50 μM. Representative images showing normal pancreas (n=4 biological samples), low-LPAR4 PDAC (n=9 biological samples), and high-LPAR4 PDAC (n=6 biological samples). Bar graph shows the relative percentage of LPAR4-low and LPAR4-high patients in the PDAC tissue array. b, Quantitative RT-PCR confirming the manipulation of LPAR4 expression in 2 pancreatic cancer cell lines (Colo-357, MIA PaCa-2) and 2 patient-derived cancer cells (79E, 34E). Data were shown as mean ± s.d. (n=4 independent experiments for Colo-357 and 79E cells with LPAR4 stable knockdown, n=3 for Colo-357, 79E, and MiaPaCa2 cells with LPAR4 ectopic expression, n=3 for 34E cells with LPAR4 stable knockdown, and n=4 for 34E with LPAR4 ectopic expression). c, Non-invasive Bioluminescence images showing tumors formed at day 10 for Colo-357+sh-CTRL+luciferase or Colo-357+sh-R4.1+luciferase of various number implanted in the pancreas of nu/nu mice. Right panel showing the luminescence intensity in a blue-to-red spectrum. d, f, Trypan blue exclusion assay showing the relative number of viable cells with or without LPAR4 expression manipulation grown in 10% serum and 2D at day 4 and day 7. e, Tumor growth rates for 1 million Colo-357 cells with or without LPAR4 expression manipulation in a subcutaneous tumor model. Data were presented as mean ± s.d. for n=8 independent samples for each group. g, Quantitative RT-PCR confirming the knockdown of LPAR1 in Colo-357 cells. h, Effects of LPAR1 knockdown using siRNA on 2D or 3D (methylcellulose sphere forming) cell growth. Data were presented as mean ± s.d. for n=3 independent experiments (d,f,g, and h). Statistical analyses were performed using two tailed unpaired one sample t-test (b,g, and h) and one-way ANOVA (d-f). Source numerical data are available in source data.
    Human Pdac Tissue Array, supplied by U.S Biomax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdac+tissue+array/human+pancreatic+cancer+tissue+arrays/pmc10280815-636-7-11
    Average 90 stars, based on 1 article reviews
    human pdac tissue array - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Pantomics Inc human pancreas cancer tissue array including 20 pdacs
    <t>a,</t> <t>Immunohistochemistry</t> staining of LPAR4 in a <t>PDAC</t> tissue array consisted of 15 PDAC samples and 4 samples of normal pancreas. Scale bar is 50 μM. Representative images showing normal pancreas (n=4 biological samples), low-LPAR4 PDAC (n=9 biological samples), and high-LPAR4 PDAC (n=6 biological samples). Bar graph shows the relative percentage of LPAR4-low and LPAR4-high patients in the PDAC tissue array. b, Quantitative RT-PCR confirming the manipulation of LPAR4 expression in 2 pancreatic cancer cell lines (Colo-357, MIA PaCa-2) and 2 patient-derived cancer cells (79E, 34E). Data were shown as mean ± s.d. (n=4 independent experiments for Colo-357 and 79E cells with LPAR4 stable knockdown, n=3 for Colo-357, 79E, and MiaPaCa2 cells with LPAR4 ectopic expression, n=3 for 34E cells with LPAR4 stable knockdown, and n=4 for 34E with LPAR4 ectopic expression). c, Non-invasive Bioluminescence images showing tumors formed at day 10 for Colo-357+sh-CTRL+luciferase or Colo-357+sh-R4.1+luciferase of various number implanted in the pancreas of nu/nu mice. Right panel showing the luminescence intensity in a blue-to-red spectrum. d, f, Trypan blue exclusion assay showing the relative number of viable cells with or without LPAR4 expression manipulation grown in 10% serum and 2D at day 4 and day 7. e, Tumor growth rates for 1 million Colo-357 cells with or without LPAR4 expression manipulation in a subcutaneous tumor model. Data were presented as mean ± s.d. for n=8 independent samples for each group. g, Quantitative RT-PCR confirming the knockdown of LPAR1 in Colo-357 cells. h, Effects of LPAR1 knockdown using siRNA on 2D or 3D (methylcellulose sphere forming) cell growth. Data were presented as mean ± s.d. for n=3 independent experiments (d,f,g, and h). Statistical analyses were performed using two tailed unpaired one sample t-test (b,g, and h) and one-way ANOVA (d-f). Source numerical data are available in source data.
    Human Pancreas Cancer Tissue Array Including 20 Pdacs, supplied by Pantomics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdac+tissue+array/pancreatic+cancer+tissue+array/pmc09763154-101-8-15
    Average 90 stars, based on 1 article reviews
    human pancreas cancer tissue array including 20 pdacs - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    BioChain Institute human pdac tissue array
    <t>a,</t> <t>Immunohistochemistry</t> staining of LPAR4 in a <t>PDAC</t> tissue array consisted of 15 PDAC samples and 4 samples of normal pancreas. Scale bar is 50 μM. Representative images showing normal pancreas (n=4 biological samples), low-LPAR4 PDAC (n=9 biological samples), and high-LPAR4 PDAC (n=6 biological samples). Bar graph shows the relative percentage of LPAR4-low and LPAR4-high patients in the PDAC tissue array. b, Quantitative RT-PCR confirming the manipulation of LPAR4 expression in 2 pancreatic cancer cell lines (Colo-357, MIA PaCa-2) and 2 patient-derived cancer cells (79E, 34E). Data were shown as mean ± s.d. (n=4 independent experiments for Colo-357 and 79E cells with LPAR4 stable knockdown, n=3 for Colo-357, 79E, and MiaPaCa2 cells with LPAR4 ectopic expression, n=3 for 34E cells with LPAR4 stable knockdown, and n=4 for 34E with LPAR4 ectopic expression). c, Non-invasive Bioluminescence images showing tumors formed at day 10 for Colo-357+sh-CTRL+luciferase or Colo-357+sh-R4.1+luciferase of various number implanted in the pancreas of nu/nu mice. Right panel showing the luminescence intensity in a blue-to-red spectrum. d, f, Trypan blue exclusion assay showing the relative number of viable cells with or without LPAR4 expression manipulation grown in 10% serum and 2D at day 4 and day 7. e, Tumor growth rates for 1 million Colo-357 cells with or without LPAR4 expression manipulation in a subcutaneous tumor model. Data were presented as mean ± s.d. for n=8 independent samples for each group. g, Quantitative RT-PCR confirming the knockdown of LPAR1 in Colo-357 cells. h, Effects of LPAR1 knockdown using siRNA on 2D or 3D (methylcellulose sphere forming) cell growth. Data were presented as mean ± s.d. for n=3 independent experiments (d,f,g, and h). Statistical analyses were performed using two tailed unpaired one sample t-test (b,g, and h) and one-way ANOVA (d-f). Source numerical data are available in source data.
    Human Pdac Tissue Array, supplied by BioChain Institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdac+tissue+array/Monkey+Tissue+Array+-+22+types+of+cyno+monkey+normal+tissues+covering+all+major+organs/pmc07766822-273-13-17
    Average 90 stars, based on 1 article reviews
    human pdac tissue array - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    Image Search Results


    (A) Representative IHC staining of ITGB3 in PDAC tissue microarrays (TMA) showing varying expression levels in non-cancer and cancer tissue sections. (B). High magnification IHC images demonstrating the expression of ITGB3 on normal pancreas and cancer cells with stromal regions. (D-I) . Scatter plots depicting the correlation between ITGB3 and key tumor-associated markers such as HIF-1α (D) , GLUT-1 (E) , VEGFA (F) , Vimentin (G) , COL1A1 (H) , and PECAM1 (I) . Pearson correlation coefficients (R) and p -values indicate statistically significant positive correlation between ITGB3 and these markers. Statistical significance was assessed using a two-tailed unpaired Student’s t-test. All quantitative data represent the mean ± SEM. ∗∗∗∗p < 0.0001.

    Journal: bioRxiv

    Article Title: ProAgio, a Novel Integrin αvβ3 Targeted Cytotoxin, Suppresses Tumor Growth and Reprograms the PDAC Microenvironment

    doi: 10.64898/2026.01.15.699725

    Figure Lengend Snippet: (A) Representative IHC staining of ITGB3 in PDAC tissue microarrays (TMA) showing varying expression levels in non-cancer and cancer tissue sections. (B). High magnification IHC images demonstrating the expression of ITGB3 on normal pancreas and cancer cells with stromal regions. (D-I) . Scatter plots depicting the correlation between ITGB3 and key tumor-associated markers such as HIF-1α (D) , GLUT-1 (E) , VEGFA (F) , Vimentin (G) , COL1A1 (H) , and PECAM1 (I) . Pearson correlation coefficients (R) and p -values indicate statistically significant positive correlation between ITGB3 and these markers. Statistical significance was assessed using a two-tailed unpaired Student’s t-test. All quantitative data represent the mean ± SEM. ∗∗∗∗p < 0.0001.

    Article Snippet: To evaluate the role of ITGB3 in PDAC, we analyzed its expression using IHC in a human PDAC tissue array (PA483-L97, Biomax) that contains 40 cancer and eight non-cancer tissues ( Supplementary Table 1 ).

    Techniques: Immunohistochemistry, Expressing, Two Tailed Test

    STING expression in human PDAC stroma and CAFs. ( a ) Groups categorized by positive, weakly positive, and negative STING expression in PDAC stroma. Representative IHC analysis of STING using a human PDAC tissue array (scale bar, 100 μm). ( b ) Percentages of the indicated groups in 40 PDAC samples. ( c ) Co-immunofluorescence staining for α-SMA (red) and STING (green) in STING positive or weakly positive or negative in stroma. ( d ) 5-AZA (0.1 nM) was administered to CAF1 and CAF2 derived from murine PDACs and incubated for 24 h.

    Journal: Scientific Reports

    Article Title: Activation of STING in pancreatic cancer-associated fibroblasts exerts an antitumor effect by enhancing tumor immunity

    doi: 10.1038/s41598-024-68061-y

    Figure Lengend Snippet: STING expression in human PDAC stroma and CAFs. ( a ) Groups categorized by positive, weakly positive, and negative STING expression in PDAC stroma. Representative IHC analysis of STING using a human PDAC tissue array (scale bar, 100 μm). ( b ) Percentages of the indicated groups in 40 PDAC samples. ( c ) Co-immunofluorescence staining for α-SMA (red) and STING (green) in STING positive or weakly positive or negative in stroma. ( d ) 5-AZA (0.1 nM) was administered to CAF1 and CAF2 derived from murine PDACs and incubated for 24 h.

    Article Snippet: The human PDAC tissue array was purchased commercially from TissueArray.com (No.PA482a).

    Techniques: Expressing, Immunofluorescence, Staining, Derivative Assay, Incubation

    a, Immunohistochemistry staining of LPAR4 in a PDAC tissue array consisted of 15 PDAC samples and 4 samples of normal pancreas. Scale bar is 50 μM. Representative images showing normal pancreas (n=4 biological samples), low-LPAR4 PDAC (n=9 biological samples), and high-LPAR4 PDAC (n=6 biological samples). Bar graph shows the relative percentage of LPAR4-low and LPAR4-high patients in the PDAC tissue array. b, Quantitative RT-PCR confirming the manipulation of LPAR4 expression in 2 pancreatic cancer cell lines (Colo-357, MIA PaCa-2) and 2 patient-derived cancer cells (79E, 34E). Data were shown as mean ± s.d. (n=4 independent experiments for Colo-357 and 79E cells with LPAR4 stable knockdown, n=3 for Colo-357, 79E, and MiaPaCa2 cells with LPAR4 ectopic expression, n=3 for 34E cells with LPAR4 stable knockdown, and n=4 for 34E with LPAR4 ectopic expression). c, Non-invasive Bioluminescence images showing tumors formed at day 10 for Colo-357+sh-CTRL+luciferase or Colo-357+sh-R4.1+luciferase of various number implanted in the pancreas of nu/nu mice. Right panel showing the luminescence intensity in a blue-to-red spectrum. d, f, Trypan blue exclusion assay showing the relative number of viable cells with or without LPAR4 expression manipulation grown in 10% serum and 2D at day 4 and day 7. e, Tumor growth rates for 1 million Colo-357 cells with or without LPAR4 expression manipulation in a subcutaneous tumor model. Data were presented as mean ± s.d. for n=8 independent samples for each group. g, Quantitative RT-PCR confirming the knockdown of LPAR1 in Colo-357 cells. h, Effects of LPAR1 knockdown using siRNA on 2D or 3D (methylcellulose sphere forming) cell growth. Data were presented as mean ± s.d. for n=3 independent experiments (d,f,g, and h). Statistical analyses were performed using two tailed unpaired one sample t-test (b,g, and h) and one-way ANOVA (d-f). Source numerical data are available in source data.

    Journal: Nature cell biology

    Article Title: Pancreatic cancer cells upregulate LPAR4 in response to isolation stress to promote an ECM-enriched niche and support tumor initiation

    doi: 10.1038/s41556-022-01055-y

    Figure Lengend Snippet: a, Immunohistochemistry staining of LPAR4 in a PDAC tissue array consisted of 15 PDAC samples and 4 samples of normal pancreas. Scale bar is 50 μM. Representative images showing normal pancreas (n=4 biological samples), low-LPAR4 PDAC (n=9 biological samples), and high-LPAR4 PDAC (n=6 biological samples). Bar graph shows the relative percentage of LPAR4-low and LPAR4-high patients in the PDAC tissue array. b, Quantitative RT-PCR confirming the manipulation of LPAR4 expression in 2 pancreatic cancer cell lines (Colo-357, MIA PaCa-2) and 2 patient-derived cancer cells (79E, 34E). Data were shown as mean ± s.d. (n=4 independent experiments for Colo-357 and 79E cells with LPAR4 stable knockdown, n=3 for Colo-357, 79E, and MiaPaCa2 cells with LPAR4 ectopic expression, n=3 for 34E cells with LPAR4 stable knockdown, and n=4 for 34E with LPAR4 ectopic expression). c, Non-invasive Bioluminescence images showing tumors formed at day 10 for Colo-357+sh-CTRL+luciferase or Colo-357+sh-R4.1+luciferase of various number implanted in the pancreas of nu/nu mice. Right panel showing the luminescence intensity in a blue-to-red spectrum. d, f, Trypan blue exclusion assay showing the relative number of viable cells with or without LPAR4 expression manipulation grown in 10% serum and 2D at day 4 and day 7. e, Tumor growth rates for 1 million Colo-357 cells with or without LPAR4 expression manipulation in a subcutaneous tumor model. Data were presented as mean ± s.d. for n=8 independent samples for each group. g, Quantitative RT-PCR confirming the knockdown of LPAR1 in Colo-357 cells. h, Effects of LPAR1 knockdown using siRNA on 2D or 3D (methylcellulose sphere forming) cell growth. Data were presented as mean ± s.d. for n=3 independent experiments (d,f,g, and h). Statistical analyses were performed using two tailed unpaired one sample t-test (b,g, and h) and one-way ANOVA (d-f). Source numerical data are available in source data.

    Article Snippet: Immunohistochemistry staining of LPAR4 or FN1 in human PDAC tissue array (US Biomax PA484a) or formalin-fixed, paraffin-embedded xenograft tumors were performed using the LPAR4 antibody (Thermo Fisher, #PA5–49727) or FN1 antibody (CST, #26836, E5H6X) following the manufacturer’s protocol.

    Techniques: Immunohistochemistry, Staining, Quantitative RT-PCR, Expressing, Derivative Assay, Luciferase, Trypan Blue Exclusion Assay, Two Tailed Test